A Multi-Site, Open-Label, Partially-Randomized Trial of the Efficacy and Safety of Fixed Dose Elbasvir/Grazoprevir (EBR/GZR) Based Regimens in French Subjects With Chronic Hepatitis C Virus (HCV) Genotype 4 Infection
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Apr 2018
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 14 Apr 2018 Results (n=31) assessing efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naive participants, presented at The International Liver Congress 2018.
- 21 Mar 2018 Planned End Date changed from 22 Oct 2018 to 29 Oct 2018.
- 21 Mar 2018 Planned primary completion date changed from 22 Oct 2018 to 29 Oct 2018.